Elite Pharmaceuticals ELTP
OTC ELTP
$0.25 +0.01 (+4.17%)
At close: Oct 21, 2026 · 4:00 PM EDT

Elite Pharmaceuticals (ELTP) Income from Continuing Operations (2010 - 2026)

Updated

Elite Pharmaceuticals' Income from Continuing Operations was $5.91 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$5.88 million a year earlier and down 68.0% from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) Income from Continuing Operations (2010 - 2026) Analysis & Trends

On a trailing twelve-month basis, Elite Pharmaceuticals' Income from Continuing Operations was $56.67 million through Jun 30, 2026; for FY2026 (ended Mar 31, 2026), it came in at $44.87 million.

  • Income from Continuing Operations shows a five-year compound annual growth rate of 61.0% (FY2021 to FY2026).
  • In earlier fiscal years, Income from Continuing Operations was -$4.4 million in FY2025, $20.15 million in FY2024 (+465.6%), $3.56 million in FY2023 (-55.7%) and $8.04 million in FY2022 (+94.0%).
  • Quarterly Income from Continuing Operations has moved between -$11.04 million (fiscal Q2 2025) and $18.59 million (fiscal Q3 2026) over five years.
  • The best year-over-year quarter for Income from Continuing Operations over five years was fiscal Q2 2024 (growth of 885.7%); the worst was fiscal Q1 2023 (a decline of 80.1%).
  • Per Business Quant data, ELTP's Income from Continuing Operations in the three fiscal quarters before Q1 2027 was $18.46 million (Q4 2026), $18.59 million (Q3 2026) and $13.7 million (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 210.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 3.62 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 2.51 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -10.50 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -246.00 Mn
10 Elite Pharmaceuticals 269.31 Mn 150.98 Mn 13.51 Mn 5.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.91 Mn
Mar 31, 2026 18.46 Mn
Dec 31, 2025 18.59 Mn
Sep 30, 2025 13.70 Mn
Jun 30, 2025 -5.88 Mn
Mar 31, 2025 16.91 Mn
Dec 31, 2024 -10.89 Mn
Sep 30, 2024 -11.04 Mn
Jun 30, 2024 615,773.00
Mar 31, 2024 3.36 Mn
Dec 31, 2023 706,354.00
Sep 30, 2023 14.93 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 -1.23 Mn
Dec 31, 2022 2.97 Mn
Sep 30, 2022 1.52 Mn
Jun 30, 2022 305,883.00
Mar 31, 2022 2.43 Mn
Dec 31, 2021 2.28 Mn
Sep 30, 2021 1.79 Mn
API Access

Elite Pharmaceuticals Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=ELTP&period=max&api_key=YOUR_API_KEY